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ABSTRACT

FLAVONOIDS

ALKALOIDS

Except for Remdesivir® no other drug or vaccine has yet been approved to
treat the coronavirus disease (COVID-19) caused by the virus known as,
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Remdesivir® an small molecule and nucleic acid analogue, it is used to treat
adults and children with laboratory confirmed COVID-19, only administrated
in hospital settings. Small molecules and particularly natural products count
for almost fifty percent of the commercially available drugs, several of them
are marketed antiviral agents and those can be a potential agent to treat
COVID-19 infections. This short review rationalized different key natural
products with known activity against coronaviruses as potential leads against
COVID-19 [1].

Approved small molecules to treat COVID-19
Chloroquine, the first small molecule Food and Drug Administration (FDA) approved to treat COVID-19, later
revoked, was inspired and developed from quinine sharing the same quinoline core (Fig. 1). Quinine is the bioactive
component, an old antimalarial agent, it was isolated from the bark of Cinchona officinalis used for centuries by the
Inca empire in South America to treat malaria and other illness [2].

Several alkaloids have shown antiviral activity, for example, Kim et al. 2019, showed
that bis-benzylisoquinoline alkaloids such as, tetrandrine (1), fangchinoline (2), and
cepharanthine (3) isolated from Stephania tetrandra and other related species of
Menispermaceae, (Fig. 3) to have potent activity against human coronavirus OC43
infection [4].

In 2005, Lin et al. studied phenolic compounds which were
evaluated for their inhibitory effects on the SARS- CoV 3CLpro.
Aloe-emodin (9) and hesperetin (10) dose-dependently inhibited
cleavage activity of the 3CLpro in in vitro cell-free and cell-based
assays, the IC50 values of aloe-emodin (9) and hesperetin (10)
were 132 μM and 60 μM, respectively [5].

Fig. 3. Chemical structure
for selected alkaloids

Fig. 4. Phenolic compounds
tested against coronaviruses.

TERPENOIDS
Euphorbia neriifolia L. is an herb local to Southeast Asia. From leaves of E. neriifolia, 23 compounds were isolated, including 22 triterpenoids and one flavonoid glycoside
[6]. The antiviral activity of all the isolated compounds was evaluated. The assay results indicated the highly influence of the antiviral activity with small differences in the
structural features of the tested compounds. Among the friedelane derivatives tested, two epimers, 3β- friedelanol and 3α-friedelanol, with difference orientation at C-3 that
affected dramatically their antiviral activity while epitaraxerol (25) (Fig. 7), a taraxerane derivative, was the most active derivative [6]. Glycyrrhizin (26), the active
component of liquorice roots, has been reported to possess moderate antiviral activity against SARS-CoV in vitro with an EC50 of 300 g/mL [7], however its full mechanism
is unclear.

Fig. 1. Quinine and chloroquine chemical
structures, dashed ellipse corresponded to the
quinoline core.

FATTY ACIDS AND POLYKETIDES- DIARYLHEPTANOIDS
The chemical structure for Remdesivir® resembles adenosine one (Fig. 2). Imagining under cryo-electron
microscopy confirm Remdesivir® latches onto the primer RNA of the virus shutting down the viral reproduction [3].

Alnus japonica and its constituents exhibit various biological properties, including anti-inflammatory, anticancer, and anti-influenza activities. The ethanol extract of the stem
bark of A. japonica exhibited PLpro inhibitory activity. Hirsutenone and rubranoside B exhibited modest activity, with IC50 values of 8.0 and 9.1 μM. These compounds also
were tested using recombinant 3CLpro expressed in vitro, where rubranoside exhibited stronger 3CLpro inhibition than the other derivatives with IC50 = 36.2 μM.

Fig. 2. Chemical structures
of Remdesivir® and adenosine.

CURRENT TRENDS AND CLINICAL TRIALS
There are several ongoing clinical trials using repurposed clinical stage or approved drugs such as remdesivir, favipiravir, lopinavir/ritonavir, hydroxychloroquine, and natural
or semisynthetic products like quercetin, colchicine, tetrandrine, desferrioxamine B, azithromycin are under investigation for treating COVID-19 patients, as well as several
vaccines are in fast phases of clinical trials. Selected examples of natural products which are in current clinical trials to treat COVID-19 are shown below.
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CONCLUSIONS
There is an urgent and critical need to identify novel medical countermeasures both for prophylactic and treatment use. Since the production of a
vaccine could take 12–18 months, and de novo development of therapies usually requires 10–17 years, repositioning clinically evaluated drugs
represents one of the most practicable strategies for the rapid identification and deployment of treatments for emerging infectious diseases such as
COVID-19.
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